Metastatic Breast Cancer 2025 UPDATE
Two Onc Docs
00:00
Second-Line and Later Options for HER2-Positive Disease
Discussion of T-DXd as second-line, toxicities, and later options including T-DM1, tucatinib combinations, lapatinib, margituximab, and neratinib.
Play episode from 06:52
Transcript
